Evotec (EVTCY) Rating Increased to Buy at Zacks Investment Research

Evotec (OTCMKTS:EVTCY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm currently has a $52.00 target price on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 11.18% from the stock’s current price.

According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “

Shares of OTCMKTS:EVTCY traded up $0.27 during mid-day trading on Tuesday, reaching $46.77. 402 shares of the company’s stock were exchanged, compared to its average volume of 1,289. The firm has a market cap of $3.41 billion, a PE ratio of 129.92 and a beta of 0.76. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.90 and a current ratio of 0.93. Evotec has a twelve month low of $27.46 and a twelve month high of $52.50.

Evotec (OTCMKTS:EVTCY) last issued its quarterly earnings results on Tuesday, November 13th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.20. The company had revenue of $111.94 million for the quarter. Evotec had a net margin of 17.48% and a return on equity of 14.85%. Sell-side analysts forecast that Evotec will post 1 EPS for the current year.

About Evotec

Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services.

Read More: Trading Penny Stocks

Get a free copy of the Zacks research report on Evotec (EVTCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit